Performance in 2025 was driven by a 7% top-line increase and 13% adjusted EPS growth, underpinned by deepening health system partnerships that contributed over $1 billion in revenue over three years. Esoteric and specialty testing achieved double-digit growth, serving as a high-margin engine that captures broader routine testing volume once physicians adopt Labcorp for complex diagnostics. The successful integration of Invitae has expanded genetic testing capabilities, with management now viewing it a ...